Real-World Treatment Patterns and Outcomes in Postmenopausal, Hormone-Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative, Metastatic Breast Cancer Patients Treated With Palbociclib Plus an Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.
Latest Information Update: 08 Oct 2024
At a glance
- Drugs Letrozole (Primary) ; Palbociclib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 04 Oct 2024 Primary endpoints has been amended.
- 09 Jul 2020 New trial record